Download Download CV

_______________________
George Sgouros, Ph.D.
_July 17, 2013_
[Date of this version]
CURRICULUM VITAE
Current Primary Appointment:
Johns Hopkins University,
School of Medicine,
Baltimore MD 21205
Professor of Radiology and Radiological Science,
Director, Radiopharm. Dosimetry Section,
Division of Nuclear Medicine, Dept. of Radiology
2007-
Current Secondary Appointments:
Johns Hopkins University,
School of Medicine,
Baltimore MD 21205
Professor of Radiation Oncology,
2008-
Johns Hopkins University,
School of Medicine,
Baltimore MD 21205
Professor of Oncology,
2009-
Name :
George Sgouros
Date of birth :
March 31, 1963
Citizenship :
United States
Office Address:
4M61 CRB II
1550 Orleans St
Johns Hopkins University, SOM
Baltimore MD 21231
Home Address:
3214 Birchmede Dr
Ellicott City MD 21042
Tel. #: 410 614 0116
E-mail: [email protected]
Fax #: 413 487-3753
Foreign Languages : Spoken - Greek
Education :
Columbia University,
School of Engineering & Applied Science
New York, New York
B.S. (Applied Physics)
1980-1984
Cornell University,
Graduate School of Medical Sciences,
New York, New York
Ph.D.
(Physiology & Biophysics)
1986-1991
Postdoctoral Training :
GS 7/19/2013
1
sgourosCV_2013_07_17
Sloan-Kettering Institute
Memorial Sloan-Kettering Cancer Center
New York, New York
Post-doctoral Research Fellow
(Medical Physics)
1991-1993
Positions and Appointments:
Memorial Sloan-Kettering Cancer Center
Memorial Hospital
New York, NY 10021
Assistant/Associate Member (Medical Physics)
Assist./Assoc. Attending Physicist
1993-1998/1998-2003
Cornell University Medical College
Cornell University
New York, NY 10021
Assistant/Associate Professor in Radiology
(Radiology)
1994-1999/1999-2003
Johns Hopkins University,
School of Medicine,
Baltimore MD 21205
Visiting Associate Professor (Radiology),
Director, Radiopharm. Dosimetry Section,
Division of Nuclear Medicine, Dept. of Radiology
2003-2005
Johns Hopkins University,
School of Medicine,
Baltimore MD 21205
Associate Professor (Radiology),
Director, Radiopharm. Dosimetry Section,
Division of Nuclear Medicine, Dept. of Radiology
2005-2007
GS 7/19/2013
2
sgourosCV_2013_07_17
Publications :
A. Peer-reviewed original research articles
1.
Bigler RE, Sgouros G. Biological analysis and dosimetry for
15
O-labeled O , CO , and CO
2
2
gases administered continuously by inhalation. J Nucl Med 1983; 24(5):431-437.
2.
Bigler RE, Zanzonico PB, Schmall B, Conti PS, Dahl JR, Rothman L, Sgouros G, MacEwen
11
EG. Evaluation of [1- C]-alpha-aminoisobutyric acid for tumor detection and amino acid
transport measurement: Spontaneous canine tumor studies. Eur J Nucl Med 1985; 10:48-55.
3.
Sgouros G, Barest G, Thekkumthala J, Chui C, Mohan R, Bigler RE, Zanzonico PB.
Treatment planning for internal radionuclide therapy: Three-dimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med 1990; 31(11):1884-1891.
4.
Sgouros G. Plasmapheresis in radioimmunotherapy of micrometastases: A mathematical
modeling and dosimetrical analysis. J Nucl Med 1992; 33:2167-2179.
5.
Sgouros G, Graham MC, Divgi CR, Larson SM, Scheinberg DA. Modeling and dosimetry of
monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. J Nucl Med 1993;
34:422-430.
6.
Sgouros G. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations.
J Nucl Med 1993; 34:689-694.
7.
Sgouros G, Chiu S, Pentlow KS, Brewster LJ, Kalaigian H, Baldwin B, Daghighian F,
Graham MC, Larson SM, Mohan R. Three-dimensional dosimetry for radioimmunotherapy
treatment planning. J Nucl Med 1993; 34:1595-1601.
8.
Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G,
Tyson D, Old LJ, Larson SM, Scheinberg DA. A phase 1B trial of humanized monoclonal
antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity.
Blood 1994; 83(7):1760-1768.
9.
Lief EP, Sgouros G, Humm JL. General solution of the radioactive parent-daughter
relationship. Med Phys 1994; 21:1739-1740.
10.
Scott AM, Macapinlac H, Zhang J, Kalaigian H, Graham MC, Divgi CR, Sgouros G,
Goldsmith SJ, Larson SM. Clinical applications of fusion imaging in oncology. Nucl Med
Biol 1994; 21:775-784.
11.
Larson SM, Divgi CR, Scott A, Sgouros G, Graham MC, Kostakoglu L, Scheinberg D,
Cheung NV, Schlom J, Finn RD. Current status of radioimmunotherapy. Nucl Med Biol
1994; 21(5):785-792.
12.
Scott AM, Macapinlac H, Divgi CR, Zhang J, Kalaigian H, Welt S, Pentlow K, Hilton S,
Graham MC, Sgouros G, Pelizzari C, Chen G, Schlom J, Goldsmith SJ, Larson SM. Clinical
GS 7/19/2013
3
sgourosCV_2013_07_17
validation of SPECT and CT/MRI registration in radiolabeled monoclonal antibody studies of
colorectal carcinoma. J Nucl Med 1994; 35:1976-1984.
13.
Scott AM, Macapinlac H, Zhang J, Daghighian F, Montamayor N, Kalaigian H, Sgouros G,
Graham MC, Yeh SDJ, Lai E, Goldsmith SJ, Larson SM. Image registration of SPECT and
CT images using an external fiduciary band and 3-D surface fitting in a case of metastatic
thyroid cancer. J Nucl Med 1995; 36:100-103.
14.
Willins J, Sgouros G. Modeling analysis of Platinum-195m for targeting individual bloodborne cells in adjuvant radioimmunotherapy. J Nucl Med 1995; 36:315-319.
15.
Ugur O, Scott AM, Kostakoglu L, Hui TE, Masterson ME, Febo R, Sgouros G, Rosa E, Mehta
B, Fisher DR, Cheung NV, Larson SM. Calculated and TLD-based absorbed dose estimates
for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse
model. Nucl Med Biol 1995; 22(1):87-93.
16.
Nikula TK, Bocchia M, Curcio MJ, Sgouros G, Ma Y, Finn RD, Scheinberg DA. Impact of
the high tyrosine fraction in complementarity determining regions: Measured and predicted
effects of radioiodination on IgG immunoreactivity. Molecular Immunol 1995; 32:865-872.
17.
Sgouros G, Jureidini IM, Scott AM, Graham MC, Larson SM, Scheinberg DA. Bone marrow
dosimetry: Regional variability of marrow-localizing antibody. J Nucl Med 1996; 37:695-698.
18.
Furhang EE, Sgouros G, Chui C-S. Radionuclide photon dose kernels for internal emitter
dosimetry. Med Phys 1996; 23:759-764.
19.
Furhang EE, Chui C-S, Sgouros G. A Monte Carlo approach to patient-specific dosimetry.
Med Phys 1996, 23:1523-1529.
20.
Kolbert KS, Sgouros G, Scott AM, Bronstein JE, Malane RA, Zhang J, Kalaigian H,
McNamara S, Schwartz L, Larson SM. Implementation and evaluation of patient-specific
three-dimensional internal dosimetry. J Nucl Med 1997; 38:301-308.
21.
Furhang EE, Chui C-S, Kolbert KS, Larson SM, Sgouros G. Implementation of a Monte
Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys 1997,
24:1163-1172.
22.
Loh A, Sgouros G, O'Donoghue JA, Deland D, Puri D, Capitelli P, Humm JL, Larson SM,
Old LJ, Divgi CR. A pharmacokinetic model of 131I-G250 antibody in patients with renal cell
carcinoma. J Nucl Med 1998; 39:484-489.
23.
Slovin SF, Scher HI, Divgi CR, Reuter V, Sgouros G, Moore M, Weingard K, Pettengall R,
Imbriaco M, El-Shirbiny A, Finn R, Bronstein J, Brett C, Milenic D, Dnistrian A, Shapiro L,
Schlom J, and Larson SM. Interferon- and monoclonal antibody 131I-labeled CC49:
outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 1998; 4:643651.
GS 7/19/2013
4
sgourosCV_2013_07_17
24.
Behr TM, Sgouros G, Vougiokas V, Memtsoudis S, Gratz S, Schmidberger H, Blumenthal
RD, Goldenberg DM, Becker W. Therapeutic efficacy and dose-limiting toxicity of Augerelectron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of
125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer
1998;76:738-748.
25.
Sgouros G. Yttrium-90 biodistribution by yttrium-87 imaging: A feasibility analysis. Med.
Phys. 1998; 25:1487-1490.
26.
Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher HI. Positron
emission tomography of a human prostate cancer xenograft: Association of changes in
deoxyglucose accumulation with other measures of outcome following androgen withdrawal.
Cancer Res, 1998; 58:3009-3014.
27.
Sgouros G, O'Donoghue JA, Larson SM, Macapinlac H, Larson JJ, Kemeny N. Mathematical
model of 5-[125I]iodo-2'-deoxyuridine treatment: Continuous infusion regimens for hepatic
metastases. Int J Radiat Biol Oncol Phys 1998; 41:1177-1183.
28.
Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F,
Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson
SM, Old LJ. Phase I/II radioimmunotherapy trial with iodine-131 labeled monoclonal
antibody (Mab) G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4:2729-2739.
29.
McDevitt MR, Finn RD, Sgouros G, Ma D, Scheinberg DA. An 225Ac/213Bi generator system
for therapeutic clinical applications: construction and operation. Appl. Radiat. Isotopes 1999;
50:895-904.
30.
Griffiths GL, Govindan SV, Sgouros G, Ong GL, Goldenberg DM, Mattes MJ. Cytotxicity
with Auger electron-emitting radionuclides delivered by antibodies. Int J Cancer 1999;
81:985-992.
31.
Sgouros G, Ballangrud ÅM, Humm JL, Jurcic JG, McDevitt MR, Erdi YE, Mehta BM, Finn
RD, Geerlings MW, Larson SM, Scheinberg DA. Pharmacokinetics and dosimetry of an
alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.
J Nucl Med, 1999; 40:1935-1946.
32.
Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of
patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med
1999; 40:2102-2106.
33.
Ballangrud ÅM, Yang W-H, Dnistrian A, Lampen NM, Sgouros G. Growth and
characterization of LNCaP prostate cancer cell spheroids. Clin Cancer Res 1999; 5:3171s3176s.
34.
Behr TM, Sgouros G, Stabin MG, Behe M, Angerstein C, Blumenthal RD, Apostolidis C,
Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W. Studies on the red marrow
dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the
radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alphaemitters. Clin Cancer Res. 1999 Oct;5(10 Suppl):3031s-3043s
GS 7/19/2013
5
sgourosCV_2013_07_17
35.
Hamacher KH, Sgouros G. A schema for estimating absorbed dose to organs following the
administration of radionuclides with multiple unstable daughters: A matrix approach. Med
Phys 1999; 26:2526-2528
36.
O‟Donoghue JA, Sgouros G, Divgi CR, Humm JL. Single dose versus fractionated
radioimmunotherapy: Model comparisons for uniform tumor dosimetry. J Nucl Med 2000;
41:538-547.
37.
Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H,
Rosai J, Robbins RJ. Prognostic value of FDG-PET scanning in patients with thyroid cancer. J
Clin Endocrinol Metab 2000; 85:1107-1113.
38.
Sgouros G, Stabin M, Erdi Y, Akabani G, Kwok C, Brill AB, Wessels B. Red marrow
dosimetry for radiolabeled antibodies that bind to marrow, bone or blood components. Med
Phys 2000; 27:2150-2164.
39.
Behr TM, Behe M, Lohr M, Sgouros G, Angerstein C, Wehrmann E, Nebendahl K, Becker W.
Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when
conjugated to internalizing antibodies. Eur J Nuc Med 2000; 27:753-765.
40.
McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang
W, Finn RD, Pellegrini V, Geerlings MW, Jr., Lee M, Brechbiel MW, Bander NH, CordonCardo C, Scheinberg DA. An alpha-particle emitting antibody (J591) for radioimmunotherapy
of prostate cancer. Cancer Res 2000; 60:6095-6100.
41.
Govindan SV, Goldenberg DM, Elsamra SE, Griffiths GL, Ong GL, Brechbiel MW, Burton J,
Sgouros G, Mattes MJ. Radionuclides linked to CD74 antibody as therapeutic agents for Bcell lymphoma: Comparison of Auger electron emitters with -particle emitters. J Nucl Med
2000; 41:2089-2097.
42.
Kolbert KS, Hamacher KA, Jurcic JG, Scheinberg DA, Larson SM, Sgouros G. Parametric
images of antibody pharmacokinetics in Bi-213-HuM195 Therapy of Leukemia. J Nucl Med
2001; 42:27-32.
43.
Hamacher KA, Den RB, Den EI, Sgouros G. Cellular dose conversion factors for alphaparticle emitting radionuclides of interest in radionuclide therapy. J Nucl Med 2001; 42:12161221.
44.
Emfietzoglou D, Kostarelos K, Sgouros G. An analytical dosimetry study for the use of
radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med 2001; 42:499-504.
45.
Barendswaard EC, Welt S, Humm JL, O'Donoghue JA, Sgouros G, Finn RD, Scott AM,
Larson SM, Old LJ. Relative therapeutic efficacy of I-125 and I-131 labeled monoclonal
antibody A33 in a human colon cancer xenograft. J Nucl Med 2001; 42:1251-1256.
46.
Ballangrud AM, Yang W, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D,
Bander NH, Scheinberg DA, Sgouros G. Response of LNCaP spheroids following treatment
GS 7/19/2013
6
sgourosCV_2013_07_17
with alpha-particle emitter (213Bi)-labeled anti-PSMA antibody (J591). Cancer Res 2001;
61:2008-2014.
47.
Thomas SR, Watson EE, Bolch WE, Brill AB, Charkes ND, Fisher DR, Hays MT, Howell
RW, Meredith RF, Robertson JS, Sgouros G, Siegel JA, Wessels BW. MIRD Pamphlet No.
18: Administered cumulated activity for ventilation studies. J Nucl Med 2001; 42:520-526.
48.
Hamacher KA, Sgouros G. Theoretical estimation of absorbed dose to organs in
radioimmunotherapy using radionuclides with multiple unstable daughters. Med Phys 2001;
28:1857-1874.
49.
DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, Humm
JL, DeNardo SJ. Rationales, evidence, and design considerations for fractionated
radioimmunotherapy. Cancer 2002; 94(4 Suppl):1332-48.
50.
Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud ÅM,
Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Targeted 
particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233-1239.
51.
O'Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G. Hematologic toxicity in
radioimmunotherapy: Dose-response relationships in I-131 labeled antibody therapy. Cancer
Biother Radiopharm 2002; 17:435-443.
52.
Behr RM, Behe M, Sgouros G. Correlation of red marrow radiation dosimetry with
myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of
radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer
Biother Radiopharm 2002; 17:445-464.
53.
Sgouros G, Squeri S, Ballangrud ÅM, Kolbert KS, Teitcher JB, Panageas KS, Finn RD, Divgi
CR, Larson SM, Zelenetz AD. Patient-Specific, 3-D dosimetry in Non-Hodgkin‟s Lymphoma
Patients Treated with 131I-anti-B1 Antibody: Assessment of tumor dose-response. J Nucl Med
2003; 44:260-268.
54.
Kolbert KS, Watson T, Matei C, Xu S, Koutcher JA, Sgouros G. Murine S-factors for Liver,
Spleen and Kidney. J Nucl Med 2003; 44 784-791
55.
Bouchet LG, Bolch WE, Blanco HP, Wessels BW, Siegel JA, Rajon DA, Clairand I, Sgouros
G. MIRD pamphlet no. 19: absorbed fractions and radionuclide S values for six age-dependent
multiregion models of the kidney. J Nucl Med. 2003; 44:1113-1147
56.
Palm S, Enmon RM, Matei C, Kolbert KS, Xu S, Pellegrini V, Zanzonico PB, Finn RL,
Koutcher JA, Larson SM, Sgouros G. Pharmacokinetics and biodistribution of 86YTrastuzumab for 90Y dosimetry in an ovarian carcinoma model: Correlative microPET and
MRI. J Nucl Med 2003; 44:1148-1155.
57.
Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD,
Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG. Cytoreduction with iodine-131-anti-
GS 7/19/2013
7
sgourosCV_2013_07_17
CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone
Marrow Transplant 2003; 32:549-56.
58.
Enmon R, Yang W, Ballangrud ÅM, Solit DB, Heller G, Rosen N, Scher HI, Sgouros G.
Combination treatment with 17AAG and acute irradiation produces supra-additive growth
suppression in human prostate carcinoma spheroids. Cancer Res 2003; 63: 8393-8399.
59.
Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA.
Pharmacokinetics and toxicity of the targetable atomic generator, actinium-225-HuM195 in
non-human primates. J Nucl Med 2004; 45:129-37.
60.
Sofou S, Thomas JL, Lin H, McDevitt MR, Scheinberg DA, Sgouros G. Engineered
liposomes for potential -particle therapy of metastatic cancer. J Nucl Med 2004; 45:253-260.
61.
Ballangrud ÅM, Yang W-H, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR,
Scheinberg DA, Sgouros G. Alpha-particle emitting atomic generator (225Ac)-labeled
Trastuzumab (Herceptin) targeting of breast cancer spheroids: Efficacy versus HER2/neu
expression. Clin Cancer Res, 2004; 10:4489-97.
62.
Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, Robbins RJ, Larson SM.
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I-PET and 3D-ID. J Nucl
Med, 2004; 45:1366-72.
63.
Kostarelos K, Emfietzoglou D, Papakostas A, Yang W-H, Ballangrud ÅM, Sgouros G.
Binding and interstitital penetration of liposomes with avascular tumor spheroids. Int J
Cancer, 2004 Nov 20;112(4):713.
64.
Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, Stabin MG,
Sgouros G. Bone marrow dosimetry using blood-based models for radiolabeled antibody
therapy: a multiinstitutional comparison. J Nucl Med 2004; 45:1725-33.
65.
Emfietzoglou D, Kostarelos K, Papakostas A, Yang W-H, Ballangrud ÅM, Song H, Sgouros
G. Liposome mediated radiotherapeutics using avascular tumor spheroids: Comparative
dosimetry study for various radionuclides, liposome systems and a targeting antibody. J Nucl
Med 2005; 46:89-97.
66.
Watchman CJ, Jokisch DW, Patton PW, Rajon DA, Sgouros G, Bolch WE. Absorbed
fractions for alpha particles in tissues of trabecular bone-considerations of marrow cellularity
within the ICRP reference male. J Nucl Med 2005; 47:1171-1185.
67.
Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA.
Efforts to control the errant products of a targeted in vivo generator. Cancer Res; 2005;
65:4888-4895.
68.
Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA. Renal tubulointerstitial changes following internal irradiation with alpha-particle emitting actinium
daughters. J Amer Soc Nephrology 2005; 16(9):2677-89.
GS 7/19/2013
8
sgourosCV_2013_07_17
69.
Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud AM, Sgouros G.
Enginering lipid vesicles of enhanced intratumoral transport capabilities: Correlating liposome
characteristics with penetration into human prostate tumor spheroids. J Liposome Res 2005;
15:15-27.
70.
Jaggi JS, Seshan SV, McDevitt MR, Sgouros G, Hyjek E, Scheinberg DA. Mitigation of
radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol
Biol Physics 2006; 64:1503-12.
71.
Sgouros G, Song H, Ladenson PW, Wahl RL. Lung toxicity in radioiodine therapy of thyroid
carcinoma: Development of a dose-rate method and dosimetric Implications of the 80 mCi
rule. J Nucl Med, 2006; 47:1977-1984 (PMC2974326).
72.
Song H, He B, Prideaux AR, Du Y, Frey EC, Kasecamp W, Ladenson PW, Wahl RL,
Sgouros G. Lung dosimetry for radioiodine therapy treatment planning in the case of diffuse
lung metastases. J Nucl Med, 2006; 47:1985-1994.
73.
Song H, Du Y, Sgouros G, Prideaux AR, Frey EC, Wahl RL. Therapeutic potential of
90
Yttrium and 131Iodine-labeled anti-CD20 monoclonal antibody in treating Non-Hodgkin‟s
lymphoma patients with pulmonary involvement: A Monte Carlo based dosimetric analysis. J
Nucl Med, 2007; 48:150-157.
74.
Prideaux AR, Song H, Hobbs RF, He B, Frey EC, Ladenson PW, Wahl RL, Sgouros G. ThreeDimensional Radiobiological Dosimetry (3D-RD): Application of radiobiological modeling to
patient-specific, 3-D imaging-based internal dosimetry. J Nucl Med, 2007; 48:1008-1016.
75.
Petoussi-Henss N, Bolch WE, Zankl M, Sgouros G, Wessels B. Patient-specific scaling of
reference s-values for cross-organ radionuclide s-values: what is appropriate? Radiat Prot
Dosimetry. 2007;127(1-4):192-6
76.
Singh Jaggi J, Carrasquillo JA, Seshan SV, Zanzonico P, Henke E, Nagel A, Schwartz J,
Beattie B, Kappel BJ, Chattopadhyay D, Xiao J, Sgouros G, Larson SM, Scheinberg DA.
Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of
neonatal Fc receptor. J Clin Invest. 2007 Sep 4;117(9):2422-2430.
77.
Sofou S, Kappel BJ, Jaggi JS, McDevitt MR, Scheinberg DA, Sgouros G. Enhanced retention
of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers. Bioconjug
Chem 2007 Nov-Dec; 18(6):2061-7 (PMC2582153).
78.
Sgouros G, Hong S. Cancer stem cell targeting using the alpha-particle emitter, 213Bi:
mathematical modeling and feasibility analysis. Cancer Biother Radipahrm. 2008 23:74-81
(PMC2977973).
79.
Baechler S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological
effective dose to the MIRD schema and possible implications in radionuclide therapy
dosimetry. Med Phys. 2008 35:1123-1134 (PMC2974633).
80.
Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, Prideaux A, Fox JJ,
Sgouros G, Kozikowski AP, Pomper MG. N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-
GS 7/19/2013
9
sgourosCV_2013_07_17
[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin
Cancer Res. 2008;14(10):3036-43 (PMC3078104).
81.
Zhao JM, Har-el Y, McMahon MT, Zhou J, Sherrry DA, Sgouros G, Bulte JWM, van Zijl
PCM. Size-induced enhancement of chemical exchange saturation transfer (CEST) contrast in
liposomes. J Am Chem Soc. 130 (15), 5178–5184, 2008 (PMC2759111).
82.
Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA, Huang LQ, Murata S,
Sgouros G, Emens LA, Reilly RT, Jaffee EM. Antibody enhanced HER-2/neu targeted
vaccine induction of CD8+ T cell responses through the Fc-activation of dendritic cells. J Clin
Invest. 2008; 118(5):1700-11 (PMC2289797).
83.
Song H, Shahverdi K, Huso DL, Esaias C, Fox J, Liedy A, Zhang Z, Reilly RT, Apostolidis C,
Morgenstern A, Sgouros G. 213Bi (alpha-emitter)-antibody targeting of breast cancer
metastases in the neu-N transgnic mouse model. Cancer Res. 2008; 68(10):3873-80
(PMC2981030).
84.
He B, Wahl RL, Du Y, Sgouros G, Jacene H, Flinn I and Frey EC. Comparison of Residence
Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment Planning Monte Carlo Simulation Studies. IEEE Trans. Med. Img. 2008; 27(4): 521-530
(PMC2588667).
85.
Song H, Shahverdi K, Huso DL, Wang Y, Fox J, Hobbs RF, Gimi B, Gabrielson K, Pomper
MG, Tsui B, Bhujwalla Z, Reilly RT, Sgouros G. An immunotolerant HER-2/neu transgenic
mouse model of metastatic breast cancer. Clin Cancer Res. 2008; 14(19):6116-25
(PMC2570093).
86.
Fu D, Tanhehco Y, Chen J, Foss CA, Fox JJ, Chong J, Hobbs RF, Fukayama M, Sgouros G,
Kowalski J, Pomper MG, Ambinder RF. Bortezomib-induced enzyme-targeted radiotherapy in
herpes virus-associated tumors. Nat Med 2008;14(10):1118-22 (PMC2709824).
87.
Baechler S, Hobbs RF, Prideaux AR, Recordon M, Bischof-Delaloye A, Sgouros G.
Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab
tiuxetan. Cancer Biother Radiopharm 2008; 23(5):633-9 (PMC2936951).
88.
Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, Green AJ,
Bouchet LG, Brill AB, Bolch WE, Sgouros G, Thomas SR. MIRD pamphlet No. 20: the
effect of model assumptions on kidney dosimetry and response--implications for radionuclide
therapy. J Nucl Med 2008; 49(11):1884-99
89.
He B, Du Y, Segars WP, Wahl RL, Sgouros G, Jacene H, Frey EC. Evaluation of quantitative
imaging methods for organ activity and residence time estimation using a population of
phantoms having realistic variations in anatomy and uptake. Med Phys 2009; 36(2):612-619
(PMC2848525).
90.
Hobbs RF, Sgouros G. Calculation of the biological effective dose for piecewise defined doserate fits. Med Phys. 2009 Mar;36(3):904-7 (PMC2736747).
GS 7/19/2013
10
sgourosCV_2013_07_17
91.
Loeb DM, Garrett-Mayer E, Hobbs RF, Prideaux AR, Sgouros G, Shokek O, Wharam MD Jr,
Scott T, Schwartz CL. Dose-finding study of (153)Sm-EDTMP in patients with poor-prognosis
osteosarcoma. Cancer. 2009 115(11):2514-22 (PMC2974628).
92.
Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD Pamphlet No. 21: A
Generalized Schema for Radiopharmaceutical Dosimetry--Standardization of
Nomenclature. J Nucl Med 2009; 50(3):477-484 .
93.
He B, Wahl RL, Sgouros G, Du Y, Jacene H, Kasecamp WR, Flinn I, Hammes RJ, Bianco
J, Kahl B, Frey EC. Comparison of organ residence time estimation methods for
radioimmunotherapy dosimetry and treatment planning – patient studies. Med Phys 2009;
36:1595-1601 (PMC2851232).
94.
Hobbs RF, Wahl RL, Lodge MA, Javadi MS, Cho SY, Chien DT, Ewertz ME, Esaias CE,
Ladenson PW, Sgouros G. 124I PET-based 3D-RD dosimetry for a pediatric thyroid
cancer patient: Real-time treatment planning and methodological comparison. J Nucl Med,
2009; 50(11):1844-1847 (PMC2844448).
95.
Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, Morgenstern A,
Sgouros G. Radioimmunotherapy of breast cancer metastases with alpha-particle-emitter
225
Ac: Comparing efficacy with 213Bi, 90Y. Cancer Res, 2009;69(23):8941-8
(PMC2789180).
96.
Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A. Pre-therapeutic 124I PET/CT
dosimetry confirms low average absorbed doses per administered 131I activity to the salivary
glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging
2010 May;37(5):884-95 (PMC2854857).
97.
Sofou S, Enmon R, Palm S, Kappel B, Zanzonico P, McDevitt MR, Scheinberg DA, Sgouros
G. Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of
micrometastatic cancer. J Liposome Res. 2010 Dec;20(4):330-40 (PMC3172685).
98.
Hobbs RF, Baechler S, Senthamizhchelvan S, Prideaux AR, Esaias CE, Reinhardt M, Frey EC,
Loeb DM, Sgouros G. Camera saturation in whole body planar imaging: An algorithmic
solution. Phys Med Biol. 2010 Feb 7;55(3):817-31 (PMC2844671).
99.
Hobbs RF, Baechler S, Wahl RL, He B, Song H, Esaias CE, Frey EC, Jacene H, Sgouros G.
Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy.
J Nucl Med, 2010 Mar;51(3):368-75 (PMC2967028).
100. Lingappa, M, Song H, Thompson S, Bruchertseifer F, Morgenstern A, Sgouros G.
Immunoliposomal Delivery of 213Bi for α-Emitter Targeting of Metastatic Breast Cancer.
Cancer Res 2010 Sep 1;70(17):6815-23 (PMC2977986).
101. Loeb DM, Hobbs RF, Okoli A, Chen AR, Cho S, Srinivasan S, Sgouros G, Shokek O,
Wharam MD Jr, Scott T, Schwartz CL. Tandem dosing of samarium-153 ethylenediamine
tetramethylene phosphoric acid with stem cell support for patients with high-risk
osteosarcoma. Cancer. 2010 Dec 1;116(23):5470-8 (PMC2991401).
GS 7/19/2013
11
sgourosCV_2013_07_17
102. Dieudonné A, Hobbs RF, Bolch WE, Sgouros G, Gardin I. Fine-Resolution Voxel S Values
for Constructing Absorbed Dose Distributions at Variable Voxel Size. J Nucl Med. 2010
Oct;51(10):1600-7 (PMC2974318).
103. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney
ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential
Cytarabine and {alpha}-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for
Acute Myeloid Leukemia. Clin Cancer Res. 2010 Nov 1;16(21):5303-11 (PMC2970691).
104. Baechler S, Hobbs RF, Jacene HA, Bochud FO, Wahl RL, Sgouros G. Predicting hematologic
toxicity in patients undergoing radioimmunotherapy with 90Y-Ibritumomab Tiuxetan or 131ITositumomab. J Nucl Med, 2010 Dec;51(12):1878-84 (PMC3169802).
105. Hobbs RF, McNutt T, Baechler S, He B, Esaias CE, Frey EC, Loeb DM, Wahl RL, Shokek O,
Sgouros G. A treatment planning method for sequentially combining radiopharmaceutical
therapy (RPT) with external radiation therapy (XRT). Int J Radiat Oncol Biol Phys, 2011
80:1256-62 (PMC3090537)
106. Senthamizhchelvan S, Bravo PE, Esaias C, Lodge MA, Merrill J, Hobbs RF, Sgouros G,
Bengel FM Human biodistribution and radiation dosimetry of 82Rb. J Nucl Med. 2011
Oct;51(10):1592-9 (PMC3172678).
107. Senthamizhchelvan S, Bravo PE, Esaias C, Lodge MA, Merrill J, Hobbs RF, Bengel FM,
Sgouros G. Radiation dosimetry of 82Rb in humans under pharmacologic stress. J Nucl Med.
2011 Mar;52(3):485-91 (PMC3172687)
108. Hobbs RF, Baechler S, Fu DX, Esaias C, Pomper MG, Ambinder RF, Sgouros G. A model of
cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy. Med Phys 2011
Jun;38(6):2892-903 (PMC3117894).
109. Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros
G, Mease RC, Pomper MG. 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging
Agent for Prostate Cancer. Clin Cancer Res 2011;17 7645-7653 (PMC3243762).
110. Sgouros G, Frey EC, Bolch WE, Wayson MB, Abadia AF, Treves ST. An approach for
balancing diagnostic image quality with cancer risk: application to pediatric diagnostic
imaging of 99mTc-dimercaptosuccinic acid. J Nucl Med. 2011; 52(12):1923-9
(PMC3290866).
111. Senthamizhchelvan S, Hobbs RF, Song H, Frey EC, Zhang Z, Armour E, Wahl RL, Loeb DM,
Sgouros G. Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene
phosphonic acid therapy of high-risk osteosarcoma. J Nucl Med. 2012;53:215-24
(PMC3291096).
112. Wayson M, Lee C, Sgouros G, Treves ST, Frey E, Bolch WE. Internal photon and electron
dosimetry of the newborn patient--a hybrid computational phantom study. Phys Med Biol.
2012; 57:1433-57 (PMC pending).
GS 7/19/2013
12
sgourosCV_2013_07_17
113. Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD.
Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors
after depletion of effector/memory-like regulatory T cells. PLoS One. 2012;7:e31962
(PMC3281086).
114. Liu G, Moake M, Har-El YE, Long CM, Chan KW, Cardona A, Jamil M, Walczak P, Gilad
AA, Sgouros G, van Zijl PC, Bulte JW, McMahon MT. In vivo multicolor molecular MR
imaging using diamagnetic chemical exchange saturation transfer liposomes. Magn Reson
Med. 2012 67:1106–1113 (PMC pending).
115. Cheng Y, Senthamizhchelvan S, Agarwal R, Green GM, Mease RC, Sgouros G, Huso DL,
Pomper MG, Meltzer SJ, Abraham JM. [( 32) P]ATP inhibits the growth of xenografted
tumors in nude mice. Cell Cycle 2012 11:1878-1882 (PMC pending).
116. Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, Flux GD, Sgouros G.
A bone marrow toxicity model for (223)Ra alpha-emitter radiopharmaceutical therapy. Phys
Med Biol. 2012 57:3207-22 (PMC pending).
117. Hobbs RF, Song H, Huso DL, Sundel M, Sgouros G. A nephron-based model of the kidneys
for macro-to-micro α-particle dosimetry. Phys Med Biol. 2012; 57:4403-24 (PMC pending).
118. Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, Ljungberg M.
MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in
Internal Radionuclide Therapy. J Nucl Med. 2012; 53:1–16 (PMC pending).
119. Baechler S, Hobbs RF, Boubaker A, Buchegger F, He B, Frey EC, Sgouros G. Threedimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor
radionuclide therapy. Med Phys. 2012; 39:6118-6128 (PMC pending).
120. Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres
CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C,
Slusher BS, Kozikowski AP, Pomper MG. Biodistribution, tumor detection, and radiation
dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane
antigen, in patients with metastatic prostate cancer.J Nucl Med. 2012 Dec;53(12):1883-91
121. Dieudonné A, Hobbs RF, Lebtahi R, Maurel F, Baechler S, Wahl RL, Boubaker A, Le
Guludec D, Sgouros G, Gardin I. Study of the Impact of Tissue Density Heterogeneities on 3Dimensinal Abdominal Dosimetry: Comparison Between Dose Kernel Convolution and Direct
Monte Carlo Methods. J Nucl Med. 2013 Feb;54(2):236-43
122. Hobbs RF, Jentzen W, Bockisch A, Sgouros G. Monte Carlo-based 3-dimensional dosimetry
of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using
124I PET. Q J Nucl Med Mol Imaging. 2013 Mar;57(1):79-91
123. Cheng L, Hobbs RF, Segars PW, Sgouros G, Frey EC. Improved dose-volume histogram
estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction
parameters. Phys Med Biol. 2013 Jun 7;58(11):3631-47.
GS 7/19/2013
13
sgourosCV_2013_07_17
124. Hobbs RF, Wahl RL, Frey EC, Kasamon Y, Song H, Huang P, Jones RJ, Sgouros G.
Radiobiological optimization of combination radiopharmaceutical therapy applied to
myeloablative treatment of non-Hodgkin‟s lymphoma. J Nucl Med, In Press.
125. Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, DeWeese TL,
Sgouros G. Targeting Aberrant DNA double strand break repair in triple negative breast
cancer with alpha particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther, In
Press.
B. Books and Other Monographs
Books:
1.
Zaidi H, Sgouros G, Ed. Monte Carlo calculations in nuclear medicine: Therapeutic
applications. Institute of Physics Publishing, 2002.
Chapters/Review Articles:
1.
Sgouros G, Scheinberg DA. The treatment of leukemia with radiolabeled monoclonal
antibodies. In: Steven T. Rosen, Timothy M. Kuzel , Editors. Immunoconjugate Therapy of
Hematologic Malignancies. Kluwer Academic Press, 23-64, 1993.
2.
Sgouros G, Scheinberg DA. Treatment of leukemia with radiolabeled monoclonal antibodies.
Cancer Treat Res 1993;68:23-64
3.
Larson SM, Sgouros G, Cheung NKV. Monoclonal Antibodies in Cancer Therapy:
Radioisotope conjugates. In: DeVita VT, Hellman S, Rosenberg SA, Editors. Biologic
Therapy of Cancer (2nd Edition), Lippincott, 534-552, 1995.
4.
Junghans RP, Sgouros G, Scheinberg DA. Antibody-based Immunotherapies for Cancer. In:
Chabner B and Longo DL, Eds. Cancer Chemotherapy and Biotherapy: Principles and
Practice, 2nd Edition, Lippincott, 655-689, 1996.
5.
Larson SM, Sgouros G, Cheung NKV. Radiolabeled Antibodies: General Issues. In: Bertino
J, Ed. Encyclopedia of Cancer, Academic Press, 1407-1431, 1996.
6.
Sgouros G. Radioimmunotherapy of Micrometastases. In: Riva P, Ed. Cancer
Radioimmunotherapy – Present and Future. Harwood Academic Publishers, 191-207, 1998.
7.
McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA.
Radioimmunotherapy with alpha-emitting nuclides. Eur J Nuc Med, 25:1341-1351, 1998.
8.
Larson SM, Divgi C, Sgouros G, Cheung NV, Scheinberg DA. Principles and Practice of
Monoclonal Antibody Therapy:Radioisotope Conjugates. In:Rosenberg SA, Editor. Principles
and Practice of the Biologic Therapy of Cancer, 3rd Edition, Lippincott, 396-412, 2000.
GS 7/19/2013
14
sgourosCV_2013_07_17
9.
Scheinberg DA, Sgouros G, Junghans RP,. Antibody-based Immunotherapies for Cancer. In:
Chabner B and Longo DL, Eds. Cancer Chemotherapy and Biotherapy: Principles and
Practice, 3rd Edition, Lippincott, 850-860, 2001.
10.
Sgouros G. Radiolabeled Antibodies: Overview. In: Bertino J, Ed. Encyclopedia of Cancer,
2nd Edition, Academic Press, 29-39, 2002.
11.
Sgouros G, Yang W-H, Enmon R. Spheriods of Prostate Tumor Cell Lines. In: Jackson P,
Russell P, Eds. Prostate Cancer: Methods and Protocols, The Humana Press, Inc., 2003.
12.
Manuel B, Kwok C, Sgouros G. Dose point-kernels for radionuclide dosimetry. In: Zaidi H,
Sgouros G, Ed. Monte Carlo calculations in nuclear medicine: Therapeutic applications.
Institute of Physics Publishing, 158-174, 2002.
13.
Sgouros G, Kolbert KS. The three-dimensional internal dosimetry software package, 3D-ID.
In: Zaidi H, Sgouros G, Ed. Monte Carlo calculations in nuclear medicine: Therapeutic
applications. Institute of Physics Publishing, 249-261, 2002.
14.
Ljungberg M, Dewarja Y, Sgouros G, Strand S. Evaluation and validation of dose calculation
procedures in patient-specific radionuclide therapy. In: Zaidi H, Sgouros G, Ed. Monte Carlo
calculations in nuclear medicine: Therapeutic applications. Institute of Physics Publishing,
262-285, 2002.
15.
Sgouros G. Dosimetric and radiobiological considerations: Patient-specific dosimetry. In:
Peter Ell, Sanjiv S. Gambhir, Eds. Nuclear Medicine in Clinical Diagnosis and Treatment,
Volume 1, 3rd Edition. Elsevier Science,375-382, 2004.
16.
Sgouros G. Dosimetry of Internal Emitters. J Nucl Med 2005;46:18S-27S
17.
Scheinberg DA, Mulford DA, Jurcic JG, Sgouros G, Junghans RP. Antibody therapies of
cancer. In: Chabner BA, Longo DL, Eds. Cancer Chemotherapy and Biotherapy: Principles
and Practice, 4th Edition, Lippincott Williams and Wilkins, 667-698, 2006.
18.
Sgouros G, Knox SJ, Joiner MC, Morgan WF, Kassis AI. MIRD continuing education:
Bystander and low dose-rate effects: are these relevant to radionuclide therapy? J Nucl Med
2007 Oct;48(10):1683-91.
19.
Sofou S, Sgouros G. Antibody-targeted liposomes in cancer therapy and imaging. Expert
Opin Drug Deliv. 2008 Feb;5(2):189-204.
20.
Sgouros G. Alpha particles for targeted therapy. Adv Drug Deliv Rev. 2008; 60(12):1402-6,
21.
Sgouros G, Frey E, Wahl R, He B, Prideaux A, Hobbs R. Three-dimensional imaging-based
radiobiological dosimetry. Semin Nucl Med 2008; 38(5):321-34.
22.
Sgouros G. Update: molecular radiotherapy: survey and current status. Cancer Biother
Radiopharm, 2008; 23(5):531-40.
GS 7/19/2013
15
sgourosCV_2013_07_17
23.
Sgouros G. High-LET-Emitting Radionuclides for Cancer Therapy. In:Stigbrand T, Carlsson
J, Adams GP, Eds. Targeted Radionuclide Tumor Therapy, Biological Aspects, Springer
Sceince+Business Media B.V., 175-181, 2008.
24.
Sgouros G. Radionuclides for Therapy. In: Pomper MG, Gelovani JG., Eds. Molecular
Imaging in Oncology, Informa Healthcare USA, 217-226, 2008.
25.
Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H,
Howell RW, Akabani G. MIRD Pamphlet No. 22 (abridged) - Radiobiology and dosimetry of
alpha-particle emitters for targeted radionuclide therapy. J Nucl Med, 2010 Feb;51(2):311-28.
Epub 2010 Jan 15
26.
Song H, Sgouros G. Radioimmunotherapy of solid tumors: searching for the right target. Curr
Drug Deliv. 2011 Jan 1;8(1):26-44.
27.
Sgouros G, Hobbs RF, Atkins FB, Van Nostrand D, Ladenson PW, Wahl RL. Threedimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid
cancer. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S41-7. Epub 2011 Apr 12
28.
Sgouros G, Hobbs RF, Song H. Modelling and dosimetry for alpha-particle therapy. Curr
Radiopharm. 2011;4:261-5.
29.
Sgouros G, Hobbs RF. Patient-Specific Dosimetry, Radiobiology, and the Previously-Treated
Patient. In: MEDICAL RADIOLOGY – Radiation Oncology, Edited by L.W. Brady, H.-P.
Heilmann, M. Molls, C. Nieder. Volume: Therapeutic Nuclear Medicine – Edited by Richard
P. Baum In Press
C. Other
Conference Proceedings:
1.
Bigler RE, Sgouros G. Radiation Dosimetry of
15
O-labeled O , CO , and CO gases
2
2
administered continuously in the breath. Nuclear Medicine and Biology, Vol II, p. 2000-2003,
C. Raynaud, Ed. Pergamon Press, New York, 1982.
2.
Bigler RE, Zanzonico PB, Cosma M, Sgouros G. Adjuvant radioimmunotherapy for
micrometastases: A strategy for cancer cure. In Radiolabeled Antibodies for Imaging and
Therapy, NATO Advanced Study Institute, Barga, Italy, July 20 - August 1, 1986. Srivastava
SC (Ed), Plenum Press, New York, pp 409-429, 1988.
3.
Zanzonico PB, Bigler RE, Sgouros G, Strauss A. Quantitative SPECT in radiation dosimetry.
Sem Nucl Med 19:47-61, 1989.
4.
Zanzonico PB, Edwards C, Sgouros G, Strauss A, Bigler RE, Hurley JR, Becker DV. Practical
dosimetry: Quantitative imaging in radionuclide therapy. In: Dosimetry of Administered
Radionuclides. Eds: Adelstein SJ, Kasis AI, Burt RW. American College of Nuclear
Physicians and Society of Nuclear Medicine. Washington DC, 1989. p 275-294
GS 7/19/2013
16
sgourosCV_2013_07_17
5.
Fisher DR, Sgouros G. Dosimetry of radium-223 and progeny. Proceedings of the 6th
International Radiopharmaceutical Dosimetry Symposium, May 7-10, 1996, Gatlinburg, TN;
Pgs. 375-391.
6.
Behr TM, Sgouros G, Sharkey RM, Dunn RM, Blumenthal RD, Kolbert KS, Juweid ME,
Siegel JA, Goldenberg DM. 90Y-Dosimetry in the nude mouse: Evaluation of three dosimetry
models in relation to the observed biological effects in the radioimmunotherapy of human
colon cancer xenografts. Proceedings of the 6th International Radiopharmaceutical Dosimetry
Symposium, May 7-10, 1996, Gatlinburg, TN.
7.
Sgouros G. Treatment planning for internal emitter therapy: Methods, applications and
clinical implications. Proceedings of the 6th International Radiopharmaceutical Dosimetry
Symposium, May 7-10, 1996, Gatlinburg, TN; pgs. 13-24.
8.
Sgouros G. Alpha Particle Emitters in Cancer Therapy: Establishing the Rationale and
Overcoming the Difficulties. Proceedings of EPSMH '96, Engineering & the Physical
Sciences in Medicine & Health Conference, October 21-24, 1996, Canberra, Australia.
9.
Sgouros G. Internal Emitter Dosimetry: Are Patient-Specific Calculations Necessary?
Proceedings of EPSMH '96, Engineering & the Physical Sciences in Medicine & Health
Conference, October 21-24, 1996, Canberra, Australia.
10.
Sgouros G. Mathematical Models of Tumour Growth: Translating Absorbed Dose to Tumour
Control Probability Proceedings of EPSMH '96, Engineering & the Physical Sciences in
Medicine & Health Conference, October 21-24, 1996, Canberra, Australia.
11.
Larson SM, El-Shirbiny AM, Divgi CR, Sgouros G, Finn RD, Tschmelitsch J, Picon A,
Whitlow M, Schlom J, Zhang J, Cohen AM. Single chain antigen binding protein (sFv CC
49): First human studies in colorectal cancer metastatic to liver. Cancer 1997;80(12
Suppl):2458-2468
12.
Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert KS, Griffiths GL,
Siegel JA, Becker WS, Goldenberg DM. Overcoming nephrotoxicity of radiometal-labeled
immunoconjugates: Improved cancer therapy in a nude mouse model in relation to the internal
radiation dosimetry. Cancer 1997; 80(12 Suppl):2591-2610.
13.
Sgouros G. Introduction to kidney dose-response for radionuclide therapy. Cancer Biother
Radiopharm 2004; 19:357 In: Sgouros, G. Wessels B., Guest Editors. Kidney Dose-Response
for Radionuclide Therapy. Cancer Biother Radiopharm 2004; 19:355-390.
14.
Meghzifene A, Sgouros G. IAEA support to medical physics in nuclear medicine. Semin Nucl
Med. 2013 May;43(3):181-7
Editorial/Commentary:
1.
DeNardo GL, Maddock SW, Sgouros G, Scheibe PO, DeNardo SJ. Immunoadsorption: An
enhancement strategy for radioimmunotherapy. J Nucl Med 1993; 34:1020-1027.
GS 7/19/2013
17
sgourosCV_2013_07_17
2.
Sgouros G. Radioimmunotherapy of micrometastases: Side-stepping the solid tumor hurdle. J
Nucl Med 1995; 36:1910-1912.
3.
Zanzonico P, Sgouros G. Prediction of myelotoxicity in radioimmunotherapy: What does
dosimetry contribute? J Nucl Med 1997; 38:1753-1754.
4.
Sgouros G. Long-lived Alpha Emitters in Radioimmunotherapy: The Mischievous Progeny.
Cancer Biother & Radiopharm 2000; 15:219-221.
5.
Behr TM, Behe M, Jungclas H, Jungclas H, Becker W, Sgouros G. Higher relative biological
efficiency (RBE) of alpha-particles for acute effects: in vitro veritas, in vivo vanitas? Eur J
Nucl Med 2001; 28:1435-6.
6.
Sgouros G. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer J Nucl
Med 2005; 46:899-900.
7.
Sgouros G. Towards patient-friendly cell-level dosimetry. J Nucl Med 2007; 48:496-497.
8.
Sgouros G. Molecular radiotherapy: Targeting cancer at the cellular level. MI Gateway,
Newsletter of the SNM Molecular Imaging Center of Excellence. J Nucl Med 2007, Dec issue.
9.
Sgouros G. Update: molecular radiotherapy: survey and current status Cancer Biother
Radiopharm 2008; 23(5):531-540
10.
Sgouros G, Howell RW, Bolch WE, Fisher DR. MIRD Commentary: Proposed Name for a
Dosimetry Unit Applicable to Deterministic Biological Effects--The Barendsen (Bd). J Nucl
Med 2009; 50(3):485-487.
11.
Wessels BW, Dale RG, Cremonesi M, Meredith RF, Green AJ, Brill B, Bolch WE, Sgouros
G, Thomas SR. Renal Dosimetry. Cancer Biother Radiopharm. 2010 Sep 28. [Epub ahead of
print].
Patents and Software Copyrights:
"Parametric image representation of imaging agent kinetics,"
Patent No.: 5684889, 11/4/1997.
"Alpha-Emitting Constructs & Uses Thereof,"
PCT application: PCT/US/99/11673
"Liposomal encapsulation of alpha-particle emitters and uses thereof,"
PCT Application: WO0197859
"Analysis and display software for multi-modality, longitudinal imaging studies: Multimodality Image Analysis Utility (MIAU),"
Copyright filed February 8, 2002
"Use of histone deacetylase inhibitors in combination with radiation for the treatment of
cancer,"
Provisional patent application: 60/373,033
GS 7/19/2013
18
sgourosCV_2013_07_17
Full List
JHTT Active
TLA
JHU
JHU File Case Number
Number
No Active TLA C04225
Aditi Martin
Filing
Country
File - Application
Number
Application Title
P04225-03 United States
Method for the Rapid B1-213 Encapsulation and
Immunolabeling of Liposomes for Targeted Alpha-Particle
Therapy of Metastatic Prostate Cancer
P04225-01 United States 60/462,739
Method for the Rapid B1-213 Encapsulation and
Immunolabeling of Liposomes for Targeted Alpha-Particle
Therapy of Metastatic Prostate Cancer
P04225-02 United States 60/668,590
Method for the Rapid B1-213 Encapsulation and
Immunolabeling of Liposomes for Targeted Alpha-Particle
Therapy of Metastatic Prostate Cancer
C04533
P04533-01 United States 60/649,472
NanoDTox-Method for in vivo Rapid Absorption and Splenic
Sequestration of Circulating Toxins and Other Biohazardous
Agents
C04642
P04642-01 United States 60/673,164
Immunoliposomal Delivery of Vaccine to the Spleen
C05056
P05056-03 United States 12/514,853
System and Method for Determining Amount of Radioactive
Material to Administer to a Patient
P05056-04 United States 12/687,670
Method and System for Administering Internal Radionuclide
Therapy (IRT) and External Radiation Therapy (XRT)
P05056-05 United States 13/335,565
Method and System for Administering Internal Radionuclide
Therapy (IRT) and External Radiation Therapy (XRT)
P05056-01 United States 60/860,315
A Dose-rate Method For Prescribing Radioiodine Treatment In
Thyroid Cancer Patients With Lung Metastases
P05056-02
System and Method for Determining Amount of Radioactive
Material to Administer to a Patient
C05116
PCT/US2007/85400
P05116-01 United States 60/860,319
Imaging-based, Three-dimensional Internal Dosimetry with
Radiobiological Modeling
P05116-02 United States 61/285,047
A practical methodology for sequentially combining internal
radionuclide therapy (IRT) and external radiation therapy
(XRT)
No Active TLA C10197
P10197-01 United States 60/999,134
Method for Targeting Cancer Stem Cells with Alpha-particle
Emitting Radionuclides
Aditi Martin
P10277-03 United States 12/811,620
Antitumor Immunization by Liposomal Delivery of Vaccine to
the Spleen
P10277-01 United States 61/009,779
Enhanced Antitumor Immunization by Liposomal Delivery of
Vaccine
C10277
P10277-02
PCT/US2009/030039 Enhanced Antitumor Immunization by Liposomal Delivery of
Vaccine
No Active TLA C10591
C10810
Aditi Martin
P10810-01 United States 61/228,241
Liposomal Conjugation of Alpha-emitters for Targeted Alphaparticle Therapy
P10810-02 United States 61/296,667
Liposomal Conjugation of Alpha-emitters for Targeted Alphaparticle Therapy
C10968
P10968-01 United States 12/690,471
METHOD AND SYSTEM FOR GAMMA CAMERA COUNT RATE
SATURATION CORRECTION
C12217
P12217-02 United States
Radiobiological Optimization of Combination
Radiopharmaceutical Therapy Applied to Myeloablative
Treatment of Non-Hodgkin's Lymphoma
P12217-01 United States 61/719,283
Radiobiological Optimization of Combination
Radiopharmaceutical Therapy Applied to Myeloablative
Treatment of Non-Hodgkin's Lymphoma
P12230-01 United States 61/731,170
METHODS OF IDENTIFYING SURROGATE IMAGING AGENTS
FOR ALPHA EMITTER RADIOPHARMACEUTICALS AND THEIR
USE IN TREATMENT OF DISEASE
C12230
Research Support (PI or Co-PI) :
ACTIVE
Title: R01CA116477 “Dose Response in Radionuclide Therapy”
Time Commitment: .2.4 calendar months
Supporting Agency:NIH/NCI – (Sgouros – PI)
GS 7/19/2013
19
sgourosCV_2013_07_17
Performance Period: 8/26/2011 - 6/30/2016
Level of Funding: $228,963
Project Goal: The project goal is to incorporate radiobiologic modeling into 3D-ID dosimetry
software; evaluate improvement in dose-response relationship using patient studies
Specific Aims: Collect dose-response studies, establish radiobiological reference human,
implement micro to macro modeling
Title: 1R01EB013558-01A1 Dose Reduction in Pediatric Molecular Imaging
Time Commitment: 2.4 Calendar months
Supporting Agency: NIBIB (Sgouros –PI)
Performance Period: 03/01/2012 – 02/29/2016
Level of Funding: $325,634
Project Goal: The objective of this proposal is to develop and validate techniques that can be
used to reduce the radiation exposure to pediatric patients undergoing molecular imaging
procedures using methods that retain the diagnostic quality of the images.
Title: Analysis of Novelos Data Sets
Time Commitments: .12 calendar month
Supporting Agency: Novelos Therapeutics Inc. (Sgouros – PI)
Performance Period: 07/01/2012 – 06/30/2017
Level of Funding: $123,948
Project Goal: Analyze data sets provided by Novelos in view of development of new nanoparticle.
Title: Modeling Targeted Alpha Particle Therapy of Cancer
Time Commitment 1.2 calendar months
Supporting Agency: NIH/NCI – (Hobbs)
Performance Period 5/10/2012 - 4/30/2016
Level of Funding Agency: $54,201
Project Goal: Aim 1: Develop and test specific organ models for the organs most at risk from aparticle radioimmuniotherapy at the anatomical or functional sub-unit level. Aim: Adapt the
idealized model to both measured murine and human parameters: aim 3: incorporate
anatomical information from human cadavers to refine the human models for clinical use. Aim 4:
Use therapeutic murine models to predict and control normal organ toxicity for in vivo model
validation.
Title: R01 CA109234 Quantitative SPECT for Targeted Radionuclide Therapy
Time Commitment: .36 Calendar months
Supporting Agency: NIH/NCI – (Frey – PI)
Performance Period: 09/15/2011 - 07/3/2016
Level of Funding Agency: $247,497
Project Goal: The major goal of this grant is to develop iterative reconstruction technique for
calculating cumulated activity, investigate advantages of longitudinal recon vs recon at each
time-point
Title: Comb. External Beam Radiotherapy with 153Sm-EDTMP to Treat High Risk
Osteosarcoma
Time Commitment: .6
Supporting Agency: NIH (Loeb-PI)
Performance Period: 6/1/13 – 3/31/18
Level of Funding: $207,500
GS 7/19/2013
20
sgourosCV_2013_07_17
Project Goal: The goal of this study is to evaluate Comb. External Beam Radiotherapy with
153Sm-EDTMP to Treat High Risk Osteosarcoma
Title: High Performance Multi-Modality Small Animal Imaging System
Time Commitment: .12
Supporting Agency: ODNIH PI: Tsui
Performance Period: 6/15/13 – 6/14/14
Level of Funding: $1,749,000
Project Goal and Specific Aims: To acquire a state-of-the-art high performance mutli-modality
small animal PET/SPECT/CT imaging system that will provide biomedical researchers at Johns
Hopkins Medical Institutes (JHMI) with unprecedentedly clear information in their small animal
studies to gain better understanding of different human diseases and to find better cure for them
to benefit public health
Title: JHU ICMIC Program
Time Commitment .24 calendar months
Supporting Agency: NIH/NCI – (Bhujwalla – PI)
Performance Period 09/22/2011- 07/31/2016
Level of Funding Agency: $890,668
Project Goal: This center grant funds an In Vivo Cellular and Molecular Imaging Center at
Johns Hopkins. The program consists of four research components, four developmental
projects, one career development award and four resources
Title: R01CA138636: BETR Therapy for Herpesvirus-associated Tumors
Time Commitment: .6 calendar months
Supporting Agency: NIH/NCI (Pomper – PI)
Performance Period: 4/1/10 to 2/28/15
Level of Funding: $336,625
Project Goal: The goal of study is to evaluate GCPII-Based Brain Imaging Agents
Specific Aims: Clinical trial of bortezomib enzyme activation therapy for cancers of viral origin.
Title: Promoter-driven Molecular Radiotherapy for Prostate Cancer
Time Commitments: 1.2 calendar months
Supporting Agency: Prostate Cancer Foundation
PI: Pomper
Performance Period: 10/15/2012 – 10/14/2014
Level of Funding: $500,000
Description of Goals: We propose a radical, new method for treating both primary and
metastatic prostate cancer (PCa).
Title: Regional Oncology Research Center
Time Commitment: .12
Supporting Agency: NCI – Nelson PI
Performance Period: 08/09/2012 – 04/30/2017
Level of Funding: $1,009,348
Project Goal: The aim of this grant: Consultation on proper choice and design of imaging
studies in clinical trials. Aim 2: prompt and accurate assessment of tumor response. Aim 3:
Image archival, anonymization and data import / export
GS 7/19/2013
21
sgourosCV_2013_07_17
PENDING
Title: A Multi-Component Nanoparticle for Treatment of Metastatic Prostate Cancer
Time Commitment: 1.2
Supporting Agency: CDMRP PI: DeWeese
Performance Period: 07/01/13 – 06/30/2016
Level of Funding: $1,975,658
Project Goals and Specific Aims: project and goals of this study are to research analyze the
multi-component nanoparticle for the treatment of metastatic prostate cancer.
Title: Small Molecule PSMA-Targeted Alpha Therapy
Time Commitment: .6
Supporting Agency: NIH PI: Pomper
Performance Period: 04/01/14 – 03/31/2019
Level of Funding: $412,893
Project Goals and Specific Aims: Major goals of TAT and this proposal are to show that the
LMW agents we propose will enable high tumor penetration and limit toxicity to normal tissues
(18, 19)
Title: BC123225 Tunable Lipid Nanocarriers for the Targeted Therapy of Advanced Breast
Cancer
Time Commitment: .36
Supporting Agency: CDMRP PI: Sgouros
Performance Period:09/01/13 – 08/31/2016
Level of Funding: $42278.43
Project Goals and Specific Aims: 1. Use the beta-particle imager at Johns Hopkins University
to measure the microdistribution of 3H-labeled doxorubicin in tumor and normal organ sections
for different liposomal constructs. 2. Develop microscopic and macroscopic
pharmacokinetic/dosimetry models that combine macroscopic pharmacokinetic data collected
using 86Y-loaded liposomes with the doxorubicin microdistribution . 3. Use these models to
simulate treatment with different liposomal constructs given their penetration kinetics as
measured in spheroids. 4. Validate these models by comparing predicted response with
measured response in spheroids and mouse models. 5.Use the validated models to project
potential treatment efficacy and toxicity in humans.
Title: SPORE in Prostate Cancer
Time Commitment: .6
Supporting Agency: NCI PI: Nelson
Performance Period: 09/01/13 – 08/31/18
Level of Funding: $1,563,772
Project Goals and Specific Aims: Project #1 aims to introduce
an entirely new imaging/therapy platform featuring the use of tumor-selective promoter driven
transgenes;
Title: Clinical development of 18F PET tracer for imaging VEGF receptors
Time Commitment: 2.38
Supporting Agency: SIBTECH PI:
Name of Procuring Contracting / Grants Officer: NIH R01 TBN SBIR Fast Trac, SibTEch,
Inc. Joseph Backer
PI: Pomper – Subaward
GS 7/19/2013
22
sgourosCV_2013_07_17
Performance Period: 12/01/13 – 11/30/16
Level of Funding: $98,133
Project Goals and Specific Aims: Description of Goals: The goal of this Fast-Track SBIR
collaboration with Johns Hopkins University is to develop through Phase I clinical trial a novel
18
F PET tracer for imaging receptors for vascular endothelial growth factor (VEGFR) in tumor
vasculature
PREVIOUS
5/1/92 - 4/30/93
Pilot-Mechanisms of Radiation Induced Activation of the Pentose
Phosphate Pathway in Rat Brain
NIH P01-CA29502 (sub-project)
PI (of P01): Richard Rivlin
Total direct costs:, $10,800
Role:PI of sub-project
10/1/92 - 9/30/96
Radioimmunotherapy of CML
NIH U01-CA58260
Total direct costs:
PI: David A. Scheinberg
Role: Leader, Modeling and Dosimetry
4/1/95 – 3/31/03
Modeling and Dosimetry for Radiolabeled Antibody Therapy
NIH R01-CA62444
Total direct costs: $2,319,458
Role: PI
6/14/95 - 6/14/97
Pharmacokinetics of Genetically Engineered Ab forms using PET
DOE 94-015
Total direct costs:
PI: Steven M. Larson
Role: Co-Inv
7/1/97 – 4/30/01
Antibody Therapy of Micrometastases
NIH R01 CA72683
Total direct costs: $674,253
Role: PI
Biological Approaches to the Treatment of Cancer; Biophysics/Nuclear
Medicine Core
NIH/NCI P01 CA33049
total direct costs: $686,500 (Core)
PI: Alan Houghton
Role: Co-PI of Core
1/1/00-12/31/04
3/1/00-3/1/03
GS 7/19/2013
NIH/NCI (P50) RFA CA-99-004
In Vivo Cellular and Molecular Imaging Centers (ICMICs); Imaging
Spheroid Growth and Vascularization, In Vivo
Total direct costs:
PI: Ronald Blasberg/Steven Larson
23
sgourosCV_2013_07_17
Role: PI of sub-project
11/1/00-10/31/03
Radiolabeled Herceptin to Increase Treatment Efficacy in Breast Cancer
Patients with Low Tumor HER2/neu Expression
Army Breast Cancer Research Program – Idea Award BC990927total
direct costs: $361,375
Role: PI
12/1/00-11/31/02
Targeted Delivery of Alpha Particle-Emitting Radionuclides and Their
Alpha-Emitting Progeny: Breast Cancer Therapy Using LiposomeEncapsulated Alpha-Emitters Army Breast Cancer Research Program –
Concept Award BC996563
Total direct costs: $83,250
Role: PI
1/1/01-12/31/02
Combined Targeted Radionuclide Therapy and Chemotherapy of Prostate
Cancer CaP CURE Award
total direct costs:, $100,000
Role: PI
5/1/03 – 1/31/07
Advances in Skeletal Dosimetry Through Microimaging
NIH R01 CA096441
PI Wesley Bolch, U. Florida
total direct costs $52,656
Role: PI of sub-contract
9/30/03-10/31/06
Therapy of Ovarian Carcinoma by Targeted Delivery of Alpha-Particles
using Immunoliposomes Capable of Retaining Alpha-Emitting Daughters
DOD OCRP – IDEA Award DOD OC02009
total direct costs: $355,222
Role: PI
12/1/04-11/30/07
Patient-Specific Dosimetry and Radiobiological Modeling of Targeted
Radionuclide Therapy
Department of Energy, Office of Science (BER), - Grant No. DE-FG0205ER63967
total direct costs:$226,611 (funding terminated after 6 mos because DOE
program supporting grant was eliminated)
Role: PI
2/9/05-11/30/09
Targeted Alpha-Particle Therapy of Metastases
NIH/NCI R01 CA113797
total direct costs: $700,000
Role: PI
3/1/05-2/28/08
Combination Treatment of Her2/Neu Expressing Breast Cancer
Metastasis by Targeted Alpha-Particle Radioimmunotherapy And
Cancer Vaccine
GS 7/19/2013
24
sgourosCV_2013_07_17
DOD BCRP USARMC W81XWH05010290– Multidisciplinary
Fellowship
total direct costs $368,786
PI: Hong Song
Role: Mentor, 10 % effort (no salary)
7/1/06-6/30/07
7/1/06 – 6/30/09
GS 7/19/2013
Enhanced Anti-Tumor Immunization by Liposomal Delivery of Vaccine
to the Spleen
DOD BCRP –USAMRMC Concept Award BC052595
total direct costs: 75,000
Role: PI
Liposomal Delivery of High LET Emitters to Cell Nuclei
Ruth L. Kirstein National Research Service Award (NRSA)
1F32CA12365 -Fellowship in Nanotechnology for Medicine
total direct costs: $143,000
PI: Yah-el Har-el
Role: Mentor, 5% effort (no salary)
25
sgourosCV_2013_07_17
Clinical Trials:
A Phase I/II Study of 131I-Tositumomab in
NA_00005743 Patients with Relapsed/Refractory Hodgkin’s
Lymphoma
12/15/2008
12:26 AM
Wahl
NA_00001081
Quantitative SPECT for Targeted Radionuclide Researcher 12/15/2008
Therapy of Non-Hodgkins Lymphoma
Prep
12:40 AM
Wahl
NA_00001712
Dose-Response in Radioimmunotherapy of
Lymphoma
Expired
12/15/2008
2:56 AM
Sgouros
NA_00002264
Dose-Response in Radionuclide Therapy of
Thyroid Cancer
Expired
12/15/2008
6:26 AM
Sgouros
4/6/2009
12:48 PM
Wahl
Approved
4/24/2009
12:42 PM
Wahl
Imaging of Viral Thymidine Kinase Activity in
NA_00032681 EBV-Associated and KSHV-Associated
Approved
Malignancies
1/25/2010
3:36 PM
Kasamon
NA_00023048 F-18-FBnTP PET imaging in healthy subjects
Approved
10/7/2010
10:05 AM
Madar
Approved
7/22/2011
1:37 PM
Sgouros
Phase 1 Biodistribution and Pharmacokinetic
NA_00019359 Study of 18F-DCFBC PSMA based PET in
Patients with Advanced Prostate Cancer
Approved
9/19/2011
4:01 PM
Cho
NA_00052286 PET imaging of mitochondria function
Approved
11/7/2011
2:54 PM
Madar
Validation of Dose Estimation Methods and
Measurement of Normal Liver Dose in Y-90
NA_00077479
Therasphere Therapy with Quantitative
Nuclear Imaging
Approved
2/13/2013
11:50 AM
Geschwind
Combination of External Beam Radiotherapy
NA_00075773 with 153Sm-EDTMP to Treat High Risk
Osteosarcoma
Approved
5/15/2013
4:25 PM
Loeb
Approved
A Phase I/II, Multi- Center, Safety and
Efficacy Study Evaluating Intravenously
NA_00015684 Administered 131- I- TM-601 in Patients with Withdrawn
Progressive and/or recurrent Malignant
Glioma
NA_00027502
NA_00050878
GS 7/19/2013
Human Biodistribution and Dosimetry of
Rubidium-82 Chloride
Absorbed dose vs Response Database in
Radiopharmaceutical Therapy
26
sgourosCV_2013_07_17
Teaching:
Imaging Physics Lecture and Problem Course, MSKCC 1995-2003 – “Radionuclides for Nuclear
Medicine,” “Single-Photon Emission Computed Tomography (SPECT),”
Physics Lectures for Nuclear Medicine Residents and Fellows, MSKCC 1995-2003 –
“Introcution to Tracer Kinetic Modeling,” “Internal Radionuclide Radiation Dosimetry”
Lectures for Nuclear Medicine Residents and Fellows, Johns Hopkins University, School of
Medicine, Radiology 2003-2005 – “Internal Radionuclide Radiation Dosimetry,” “Introduction to
Radiobiology I and II”
“Modern Biomedical Imaging Instrumentation and Techniques” Johns Hopkins University
Engineering School course: ECE 520.434/ BME 580.472, Radiation Dosimetry/Radiobiology
lecture 2009"Modeling and Dosimetry of Radiolabeled Antibody Therapy" Seminar in Medical Physics,
Columbia University, Dept. of Applied Physics, New York NY, 1995
“Dosimetry and Treatment Planning for Radioimmunotherapy: Future Directions” Refresher
Course, Annual Meeting of the American Association of Physicists in Medicine, Boston, MA,
1995
"Radioimmunotherapy of Micrometastases: Alpha Particle Targeting of Multicellular Spheroids"
Columbia University, Seminar in Medical Physics, Dept. of Applied Physics, New York NY,
1998
"Dosimetry of Alpha Particles in Pre-Clinical and Clinical Studies"
Categorical Seminar, Speaker Annual Meeting, Society of Nuclear Medicine, St. Louis MO,
2000.
“Kidney Dose-Response for Radionuclide Therapy”
Continuing Education Session, Organizer/Moderator, Society of Nuclear Medicine
New Orleans, LO 2003
“Bystander and low-dose rate effects”
Continuing Education Session, Organizer/Moderator, Society of Nuclear medicine
San Diego, CA 2006
“Update on Dosimetry-Based Techniques in Thyroid Cancer”
CME course: Nuclear Oncology from Genotype to Targeted Radionuclide Therapy
Johns Hopkins University, Baltimore MD March 2008
“Targeted Therapy with Alpha-Particle Emitters - Dosimetry”
CME course: Nuclear Oncology from Genotype to Targeted Radionuclide Therapy
Johns Hopkins University, Baltimore MD March 2008
“Quantities and Units related to Deterministic Effects”
CME Course, Society of Nuclear Medicine, Annual Meeting
GS 7/19/2013
27
sgourosCV_2013_07_17
San Antonio, TX 2011
“Dosimetry, Radiobiology in Radiopharmaceutical Diagnosis and Therapy (i.e., nuclear
medicine)”
e-Radiology Physics Lecture Series,
Johns Hopkins University, Baltimore MD May 2012
“Future Directions for Individualized Pediatric Dosing Guidance”
MIRD CME Course, Society of Nuclear Medicine, Annual Meeting
Miami FL June 2012
“Quantifying Patient Risk in RIB Protocols and Clinical Trial Design”
MIRD CME Course, Society of Nuclear Medicine and Molecular Imaging, Annual Meeting
Miami FL June 2012
Mentoring:
John D. Willins, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics
Co-advisor (w/ Clift Ling, Ph.D., MSKCC); „93–„94, 1st prize Young Investigator, AAPM, 2000
Present position: Chief Medical Physicist, Dept. of Rad. Onc., Boston Medical Center, Boston,
MA
Eli E. Furhang, Columbia University Grad Student, Applied Physics
Co-Ph.D. Advisor (w/ Chen Chui, Ph.D., MSKCC); „95-„97, Ph.D. awarded in „97
Present position: Physics Director, Beth-Israel Medical Center, New York, NY
Åse M. Ballangrud, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics
Advisor 6/97 – 8/00, received Army IDEA award in 2000
Present position: Assistant Attending Physicist, Assistant Member, Medical Physics, MSKCC,
New York, NY
Klaus A. Hamacher, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics
Advisor 12/97 – 5/01,
Present position: Medical Physicist, MSKCC, New York, NY
Stig Palm, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics
Advisor 3/01 – 3/03, 1st prize, Med Phys young investigator NY RAMPS, 2002
Present position: Assist. Prof.-on leave, Dept. of Radiation Physics, Göteborg University,
Sweden, Medical Physicist - Nuclear Medicine Dosimetry and Medical Radiation Physics
Section, International Atomic Energy Agency (IAEA).
Richard Enmon, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics
Advisor 6/01 – 3/03,
Present position: Associate in the Intellectual Property Group, King & Spalder, New York.
Stavroula Sofou, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics
Advisor 10/01 – 3/03, Graduate Research Grant, Hellenic Univ. Club of New York
Present position: Assist. Prof., Dept. of Chem. Engineering, Polytechnic Institute of New York
University, New York
GS 7/19/2013
28
sgourosCV_2013_07_17
Hong Song, Post-doctoral fellow, Johns Hopkins University, School of Medicine, Radiology
Awarded Multidisciplinary Post-Doctoral Fellowship Award from Department of Defense Breast
Cancer Research Program (BCRP). Titled: “Combination Treatment of HER2/neu Expressing
Breast Cancer Metastasis by Targeted alpha-Particle Radioimmunotherapy and Cancer Vaccine”.
Promoted to Research Associate in 2008
Received an exploratory grant award, “Targeting metastatic pancreatic cancer stem cells by alpha
particle radiation” from the Maryland Stem Cell Research Fund in 2009, 7/1/2009-6/30/2011,
207k direct.
Assist Prof., Dept of Radiology, Johns Hopkins University, School of Medicine
Advisor 12/03 – 6/09
Yah-el Har-el, Post-doctoral fellow, Johns Hopkins University, School of Medicine, Radiology
Awarded the Ruth L. Kirstein National Service Award Fellowship (NIH), Project title:
“Liposomal Delivery of High LET Emitters to Cell Nuclei”
Advisor 6/05 – 12/09
Andrew Prideaux, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology
Advisor 5/05 –6/08
Present position: Clinical Applications Specialist, Hermes Medical Solutions, Stockholm,
Sweden
Mohanambe Lingappa, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology
Awarded the Multidisciplinary Post-Doctoral Fellowship Award from the Department of Defense
Breast Cancer Research Program (BCRP), Project title: “Anti-tumor immunization by liposomal
delivery of vaccine to the spleen”
Advisor 4/06 –2010
Robert Hobbs, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology
Advisor 5/06 –2012
Present position: Asssistant Professor, Johns Hopkins University, SOM, Radiology
Sebastien Baechler, Visiting fellow, University Institute of Radiation Physics, Lausanne
University, Lausanne, Switzerland. Recipient of a Swiss National Science Foundation:
fellowship No. PBFR2-115886.
Advisor 3/07-3/08
Wietske van der Weg, Visiting fellow, Department of Nuclear Medicine, Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands.
Advisor 9/11-11/11
Senthamizhchelvan Srinivasan, Post-doctoral fellow, Johns Hopkins University, SOM,
Radiology
Advisor 10/08 –7/12
Donika Plyku, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology
Advisor 8/12 –
GS 7/19/2013
29
sgourosCV_2013_07_17
Ph.D. Thesis committees:
Kristina Norrgren, “Radiolabeled Monocolonal Antibodies, Development of a New Method to
Remove Circulating Activity – Diagnostic Applications and Implications for Therapy,” Guest
opponent, oral defense, Lund, Sweden, 1993.
Eli Furhang, “A Monte Carlo-Based Dosimetry Method For Patient-Specific Internal Emitter
Therapy” Columbia University Grad Student, Applied Physics
Co-Ph.D. Advisor (w/ Chen Chui, Ph.D., MSKCC); „95-„97
Peter S. Kim, “Characterization of the Biophysical, Molecular, and Immunological
Consequences of Antibody-Tumor Interaction on the Development of Potent Antitumor
Immunity,” Johns Hopkins University, School of Medicine, Department of Pharmacology and
Molecular Sciences
Thesis Advisory Committee Member 2005-2007
Bin He, Medical Imaging Physics Division, Department of Radiology
Examining Committee Member, 2005-2006, Ph.D
Chris Watchman, “Alpha Particle Dosimetry: 3D Image based Models of Normal Bone for use in
Radionuclide Therapy,” University of Florida, Department of Nuclear and Radiological
Engineering.
Thesis Advisory Committee Member 2003-2005
Andrew L. DuFresne Johns Hopkins University, School of Medicine, Biochemistry, Cellular, and
Molecular Biology Program
Thesis Advisory Committee Member 2008Michael Wayson “Computational internal dosimetry methods as applied to the University of
Florida series of hybrid phantoms” University of Florida, J. Crayton Pruitt Family Department of
Biomedical Engineering. Examining Committee Member 2011-2012.
Lishui Cheng “Development and characterization of convergent and fast penalized SPECT image
reconstruction methods for targeted radionuclide therapy dosimetry”
Thesis Advisory Committee Member 2011-2013
Xing Rong “Development and evaluation of quantitative Y-90 bremsstrahlung SPECT methods”
Thesis Advisory Committee Member 2011-2013
Editorial Activities:
Reviewer: Cancer Biotherapy and Radiopharmaceuticals, Cancer Research, Clinical Cancer
Research, International Journal of Cancer, Journal of Nuclear Medicine, Medical Physics,
Physics in Medicine and Biology, International Journal of Radiation Biology, PLoS
Guest Editor: Medical Physics, Journal of Nuclear Medicine
Editorial Board Member: Cancer Biotherapy and Radiopharmaceuticals
GS 7/19/2013
30
sgourosCV_2013_07_17
Scientific and Medical Societies :
Society of Nuclear Medicine
American Association of Physicists in Medicine
American Association for Cancer Research
American Association for the Advancement of Science
Committees/Review Panels:
Steering Committee Member (1995-2000),
American Association of Physicists in Medicine (AAPM),
Task Group on Internal Emitter Dosimetry
Chairman (1996), Dosimetry, Physics and Radiobiology Panel,
Department of Energy,
Alpha-Emitters for Medical Therapy Workshop
Chairman (1997-2003), Sub-Committee on Non-Human Use,
Committee on Radiation,
Memorial Sloan-Kettering Cancer Center
Study Section Member ('97, '98),
Biomedical Research Technology Special Emphasis Panel
National Center for Research Resources, National Institutes of Health
NCI Study Section Site Visit, City of Hope National Medical Center (‟99)
Study Section member, Advanced Nuclear Medicine Initiative, Dept. of Energy ('00)
Member (2000 - ), Vice Chairman (2006 - 2008), Chairman (2008 - )
Medical Internal Radiation Dose (MIRD) Committee,
Society of Nuclear Medicine
Oncological Sciences IRG Study Section Boundaries Team member (2001),
NIH, Center for Scientific Review
"develop recommendations for … study sections that will be responsible for
reviewing grant applications in the oncological sciences"
Member, National Council on Radiation Protection and Measurements (NCRP), Scientific
Committee 6-3, Uncertainties in Internal Radiation Dosimetry (2005-2010)
Member, Board of Directors, Molecular Imaging, Center of Excellence,
Society of Nuclear Medicine (2007)
DOD Breast Cancer Research Program (2007, 2008)
Member, Breast Cancer Review Training Panel
Study Section Member (2008)
NIH, National Institute of Allergy and Infectious Diseases, Special Emphasis Panel
Mechanisms, Diagnosis, and Treatment of Radiation Injury
from Nuclear Accident or Terrorist Attack
GS 7/19/2013
31
sgourosCV_2013_07_17
Organizing Committee Member (2009)
International Atomic Energy Association (IAEA), International Symposium on Standards,
Applications and Quality Assurance in Medical Radiation Dosimetry,
Chair, Organizing Committee (2008-2009), International Symposium on Radionuclide
Therapy and Radiopharmaceutical Dosimetry (ISRTRD)
DOD Breast Cancer Research Program (2010)
Member, Breast Cancer Review Training Panel
Study Section Member (2010)
NIH, NIBIB, Special Emphasis Panel
Training/Career Opportunity Awards
Ad Hoc Reviewer (2011),
Transplantation, Tolerance and Tumor Immunology (TTT) Study Section NIH
Scientific Advisor (2012- )
Metrology for Molecular Radiotherapy (MetroMRT) grant from the European Metrology
Research Programme, Joint Research Proposal
Standing Study Section Member (2012-)
NIH, Radiation Therapeutics and Biology (RTB)
Council Member, (2012-)
National Council on Radiological Protection and Measurements (NCRP)
Member, Scientific Committee of the IAEA/WHO Network of Secondary Standards
Dosimetry Laboratories, (2014-)
Honors & Awards :
National Physics Honor Society
1983
National Engineering Honor Society
1983
Departmental nomination for
George Vincent Wendell Award
Columbia University, Applied Physics Dept.
1984
Cancer Research Institute/Jesselson Foundation Fellowship
1991
First Prize, American Association of Physicists in Medicine,
Young Investigator Award - John Willins Awardee
George Sgouros - senior author and supervisor.
1993
Louise and Allston Boyer Young Investigator Award,
Memorial Sloan-Kettering Cancer Center,
1998
CaP CURE Award
2001
Invited Talks, Panels :
GS 7/19/2013
32
sgourosCV_2013_07_17
"Radiation Effects on Brain Glucose Metabolism: Potential for Early Prediction of Damage using
PET and MRS," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New
York, 1989.
"Conformal Treatment Planning for Radioimmunotherapy" Nuclear Medicine Seminar,
Memorial Sloan-Kettering Cancer Center, New York, 1992
"Conformal Treatment Planning for Radioimmunotherapy" Center for Molecular Medicine and
Immunology, Garden State Cancer Center, Newark, New Jersey, 1993
"Physicists Role in Clinical Radioimmunodiagnosis and Therapy" Scientific Symposium,
Annual Meeting of the American Association of Physicists in Medicine, Washington, D.C., 1993
"The Role of Modeling and Dosimetry in Achieving Success with Radioimmunotherapy"
Nuclear Medicine Seminar,
Memorial Sloan-Kettering Cancer Center, New York, 1993
“Modeling and Dosimetry for Radiolabeled Antibody Therapy” Rheumatology Grand Rounds,
Hospital for Special Surgery, New York, 1994
"Modeling and Dosimetry of Radiolabeled Antibodies: Identifying the Optimal Parameters for
Radioimmunotherapy"
Brookhaven National Laboratory, Upton, New York 1995
"Treatment Planning for Internal Emitter Therapy: Methods, Applications, and Clinical
Implications" Invited Paper, 6th International Radiopharmaceutical Dosimetry Symposium,
Gatlinburg TN 1996
"Alpha Particle Emitters in Cancer Therapy: Establishing the Rationale and Overcoming the
Difficulties," "Internal Emitter Dosimetry: Are Patient-Specific Calculations Necessary?"
"Mathematical Models of Tumour Growth: Translating Absorbed Dose to Tumour Control
Probability"
Keynote Speaker, Engineering & Physical Sciences in Medicine & Health Conference, Canberra,
Australia, 1996
"Patient-Specific Dosimetry," invited presentation, International Research Group in
Immunoscintigraphy and Immunotherapy,
Barcelona, Spain, May 1998.
"Patient-Specific Dosimetry," invited presentation, International Research Group in
Immunoscintigraphy and Immunotherapy,
Göttingen, Germany, May 1999.
"Spheriod Studies with Alpha-Emitter Labeled Antibodies"
Nuclear Medicine Seminar,
Memorial Sloan-Kettering Cancer Center, New York, 2000.
GS 7/19/2013
33
sgourosCV_2013_07_17
"Preliminary Experience with Three-Dimensional Dose Assessment and Treatment Planning"
Continuing Education session, Annual Meeting, Society of Nuclear Medicine, St. Louis MO,
2000.
"Dosimetry for Antibody and Peptide based Radionuclide Therapy"
Nuklearmedizinische Klinik und Poliklinik,
Technische Universität Munchen, 2000.
"Patient Dosimetry for 213Bi-HuM195"
Medical Internal Radionuclide Dose (MIRD) Committee meeting
Delray Beach, FL, 2000
“Clinical Dosimetry Studies”
Invited Presentation, 7th International Radiopharmaceutical Dosimetry Symposium
Nashville TN 2002
“Radionuclide Therapy and Dosimetry”
Invited Presentation, European Association of Nuclear Medicine Annual Congress
Vienna, Austria 2002
"Alpha-Particle Emitter (225Ac)-labeled Herceptin Antibody Targeting of Breast Cancer: Efficacy
Vs. HER-2/neu Expression"
Invited Presentation, Era of Hope, DoD Breast Cancer Research Program Meeting
Orlando, FL, 2002
“The Radiation Physics of Targeted Therapy”
Educational Symposium, Society of Nuclear Medicine mid-winter meeting
Anaheim, CA. 2004
“Predicting Response and Toxicity: The Role of Dosimetry”
2nd International Workshop on Nuclear Oncology
Aventura, FL. 2004
“Innovations in Tumor Dosimetry – Implications for Radioisotope Therapy Treatment Planning”
Categorical Seminar, Society of Nuclear Medicine
Philadelphia, PA. 2004
Panel Discussion: “The Future of Radioimmunotherapy,” Panel Member, 10 th Conference on
Cancer Therapy with Antibodies and Immunoconjugates,
Princeton NJ, 2004
“Trends in Dosimetry for Therapy,”
Translational Applications of Molecular Imaging and Radionuclide Therapy
Toronto, Canada. 2005
"Pre-Clincial Model for Targeted Alpha-Emitter Therapy of Early Breast Cancer Metastases,"
Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center,
New York NY 2005
GS 7/19/2013
34
sgourosCV_2013_07_17
"Radioimmunotherapy and Lack of Dosimetry and Standards,"
14th Annual Meeting Council on Ionizing Radiation and Measurement Standards
Gaithersburg MD 2005
"Skeletal Dosimetry at Johns Hopkins University," Mini-Symposium on Skeletal Dosimetry
Advanced Laboratory for Radiation Dosimetry Studies, Dept. of Nuclear and Radiological
Engineering, University of Florida,
Gainesville FL 2005
“Dosimetry for Radionuclide Therapy,”
Fudan University Hospital,
Shanghai, China 2005
"New Dosimetric Methods: Voxel-based Dosimetry"
European Association of Nuclear Medicine, Annual Meeting; 2nd International Symposium on
Radionuclide Therapy and Radiopharmaceutical Dosimetry
Athens, Greece 2006
"Radiation Biology and Individual Patient Dosimetry in Therapeutic Nuclear Oncology"
World Congress of Nuclear Medicine and Biology
Seoul, S. Korea 2006
“Modeling and Dosimetry for Targeted Radionuclide Therapy”
MD Anderson Cancer Center
Department of Experimental Diagnostic Imaging
Houston TX 2007
“Radioimmunotherapy and Targeted Alpha-Particle Therapy”
The Baltimore-Washington Chapter of the Health Physics Society
and The Mid-Atlantic Chapter of the American Association of Physicists in Medicine
Columbia, MD 2007
“Regional (AFRA) training course on medical internal dosimetry relevant to nuclear medicine.”
International Atomic Energy Agency
Technical Cooperation Project
RAF/6/032: Promoting Regional and National Quality Assurance Programmes for
Medical Physics in Nuclear Medicine (AFRA II-7)
Tunis, Tunisia, N. Africa Nov. 2007
“Update on Dosimetry-Based Techniques in Thyroid Cancer”
CME course: Nuclear Oncology from Genotype to Targeted Radionuclide Therapy
Johns Hopkins University, Baltimore MD March 2008
“Targeted Therapy with Alpha-Particle Emitters - Dosimetry”
CME course: Nuclear Oncology from Genotype to Targeted Radionuclide Therapy
Johns Hopkins University, Baltimore MD March 2008
“Antibody-Targeted Liposomes in Cancer Therapy and Imaging”
Pfizer, Inc. Cambridge MA April 2008
GS 7/19/2013
35
sgourosCV_2013_07_17
“The Emerging Role of Radiotherapeutics in Oncology”
Grand Rounds, FDA, Silver Spring MD April 2008
“Radionuclide Therapy and Dosimetry in Nuclear Medicine”
Scientific Symposium, Annual Meeting of the American Association of Physicists in Medicine,
Houston, TX, July 2008
“Dosimetry for Radionuclide Therapy”
Oncology Research Institute (ORI)/NUMI & Cancer Research Centre of Excellence,
National University of Singapore,
Singapore Novemeber 2008
“Radionuclide Dosimetry and Targeted Alpha-Emitter Therapy”
Grand Rounds, Department of Radiation Oncology and Molecular Radiotherapeutics, Johns
Hopkins University, School of Medicine,
Baltimore MD, March 2009.
“Immunoliposomes for Targeted Radionuclide Therapy”
Scientific Symposium, Annual Meeting of the American Association of Physicists in Medicine,
Anaheim, CA, July 2009
“Targeted Alpha-Particle Emitter Therapy of Metastatic Breast Cancer”
Translational Research Conference, Johns Hopkins University, School of Medicine,
Baltimore MD, October 2009
“Targeted alpha-emitter therapy and Patient-Specific 3D-Radiobiological Dosimetry (3D-RD)"
Radiation Epidemiology Branch, NIH NCI
Bethesda MD, October 2009
“3D-RD Patient-Specific Dosimetry for Thyroid Cancer”
Washington Hospital Center,
Washington DC, December 2009
“Introduction: Internal Dosimetry for Radionuclides,”
Joint International Center for Theoretical Physics-International Atomic Energy Association
Advanced School on Internal Dosimetry
Trieste, Italy, April 2010
“3D-RD Imaging-Based Dosimetry,”
Joint International Center for Theoretical Physics-International Atomic Energy Association
Advanced School on Internal Dosimetry
Trieste, Italy, April 2010
“Bexxar Dosimetry,”
Joint International Center for Theoretical Physics-International Atomic Energy Association
Advanced School on Internal Dosimetry
Trieste, Italy, April 2010
GS 7/19/2013
36
sgourosCV_2013_07_17
“2009 MIRD Committee Recommendations for Unifying MIRD and ICRP Formulas, Quantities,
and Units,”
Joint International Center for Theoretical Physics-International Atomic Energy Association
Advanced School on Internal Dosimetry
Trieste, Italy, April 2010
“PET Quantification,”
Joint International Center for Theoretical Physics-International Atomic Energy Association
Advanced School on Internal Dosimetry
Trieste, Italy, April 2010
“Dosimetry for Targeted Radionuclide Therapy,”
Workshop: Functional Imaging for Radiotherapy
Vancouver, Canada, April 2010
“Modeling and Dosimetry for Targeted Radionuclide Therapy”
SCK-CEN, Belgian Nuclear Research Centre
Mol, Belgium, July 2010
“Modeling and Dosimetry for Targeted Radionuclide Therapy”
Munich Technical University
Munich, Germany, July 2010
“Patient-Specific Dosimetry and Targeted alpha-emitter therapy”
Brigham and Women‟s Hospital, Dana Farber Cancer Institute
Boston MA October, 2010
Keynote lecture, “Alpha-Particle Emitter Therapy: Radiobiology and Dosimetry”
Targeted Alpha-Radionuclides to Combat Cancer (TARCC) Consortium Congress,
Ljubljana, Slovenia, November 2010
Keynote lecture, “Dosimetry in Radiopharmaceutical Therapy”
Swiss Society of Radiobiology and Medical Physics, Annual Meeting
Bern, Switzerland, November 2010
“Dosimetry for Radiopharmaceutical Therapy: Past, Present and Future”
CME Course, Society of Nuclear Medicine, Mid-Winter Meeting
Palm Springs CA, January 2011
“Dosimetry for Radiopharmaceutical Therapy”
Division of Medical Imaging Physics, Dept. of Radiology
Johns Hopkins University, SOM,
Baltimore MD, March 2011
“Targeted Alpha-Particle Emitter Therapy of Breast Cancer: Sidestepping some of the Biological
Obstacles to Treatment Efficacy”
Breast Cancer Novel Therapeutics/Correlative Sciences Working Group, Med Onc
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital
Baltimore MD May 2011
GS 7/19/2013
37
sgourosCV_2013_07_17
“Alpha-Particle Emitter Therapy: A New and Promising Cancer Therapy”
Invited Opponent, Ph.D. defense of Thomas Bäck
Gothenburg University
Gothenburg, Sweden May 2011
“Quantities and Units related to Deterministic Effects”
CME Course, Society of Nuclear Medicine, Annual Meeting
San Antonio, Texas, June 2011
“Alpha-Particle Emitter Dosimetry: The Fallible Mean”
7th Symposium on Targeted Alpha Therapy,
Berlin, Germany July 2011
IAEA Consultant‟s meeting on internal dosimetry
Vienna, Austria September 2011
“Dosimetry in Radiopharmaceutical Diagnosis and Therapy”
FDA Visiting Professor Lecture
Silver Spring MD, December 2011
“Evolution in Modeling and Dosimetry of Radioimmunotherapy”
World Radioimmunoconjugate Summit
Washington DC, January 2012
“I-124 PET/CT in Patient-Specific Thyroid Dosimetry for Treatment Planning”
21st Interdisciplinary Medical Symposium, 251st Air Force General Hospital
Athens, Greece, February 2012
IAEA Consultant‟s meeting on IAEA contributions to Nuclear Medicine Physics
Vienna, Austria June 2012
“Individualized Pediatric Dosing Guidance”
Royal Marsden Hospital and Institute of Cancer Research,
Sutton, UK June 2012
Scientific Advisor,
European Metrology Centres grant member‟s meeting on Metrology for Molecular Radiotherapy
London, UK June 2012
“How to Improve Dosimetry for Radiopharmaceutical Therapy,”
“Alpha-Emitters in Nuclear Medicine Therapy: Overview”
Annual Congress of the European Association of Nuclear Medicine
Milan, Italy October 2012
Scientific Advisor,
European Metrology Centres grant member‟s meeting on Metrology for Molecular Radiotherapy
Delft, Netherlands December 2012
GS 7/19/2013
38
sgourosCV_2013_07_17
“Radiopharmaceutical Dosimetry Workshop”
“Treatment Planning and Dosimetry for Alpha-Emitters”
World Radioimmunoconjugate Summit
Washington DC, February 2013
“Treatment Planning for Alpha-Emitter Therapy”
2nd World Congress on Ga-68, Molecula Imaging, Targeted Radionuclide Therapy and
Dosimetry
Chandigarh, India, March 2013
“Targeted Alpha-Emitter Therapy of Breast Cancer:
Pathways to a Phase I trial”
Breast Cancer Novel Therapeutics/Correlative Sciences Working Group, Med Onc
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital
Baltimore MD March 2013
“Physics of Radionuclide Therapy”
NCI/SNMMI joint workshop on Targeted Radionuclide Therapy
National Institutes of Health Campus
Bethesda MD March 2013
“Matching the Method with the End-Point: Dosimetry for Radiopharmaceutical Therapy”
Cancéropôle International Young Investigators Workshop: Radiobiology Applied to Oncology
Domaine de Ramonjuan – Vallée de Lesponne
France April 2013
“Radiobiology and Mechanism of Action of Radium-223”
prIME Oncology Symposium, SNMMI Annual Meeting
Vancouver BC,
Canada June 2013
“Dosimetry and Radiobiology of alpha-Particle Emitters”
IAEA Technical Meeting on:
Alpha Emitting Radionuclides and Radiopharmaceuticals for Therapy
Vienna, Austria June 2013
Scientific Advisor,
European Metrology Centres grant member‟s meeting on Metrology for Molecular Radiotherapy
Rome, Italy July 2013
“Treatment Planning for Alpha-Emitter Radiopharmaceutical Therapy”
Workshop on Innovative Personalized Radioimmunotherapy
Nantes, France July 2013
GS 7/19/2013
39
sgourosCV_2013_07_17